

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Dermatology				
Dermal ulcers	Heat shock protein 90 (Hsp90); platelet derived growth factor BB (PDGFBB)	<p>Studies in mice identified an Hsp90-derived peptide that could help promote wound healing. Previous studies have shown that the wound healing effects of PDGFBB require Hsp90. In mouse models of acute and chronic diabetic wounds, a topical Hsp90-derived peptide decreased wound size more quickly than Regranex becaplermin. Next steps include producing the peptide under GMP guidelines and testing it in pig wound models. Regranex, a gel formulation of recombinant PDGFBB, is marketed by Johnson & Johnson to treat diabetic foot ulcers.</p> <p>SciBX 4(44); doi:10.1038/scibx.2011.1235 Published online Nov. 10, 2011</p>	<p>Patented; available for licensing from the University of Southern California Stevens Institute for Innovation Contact: Chris Moulding, University of Southern California Stevens Institute for Innovation, Los Angeles, Calif. phone: 213-821-0945 e-mail: moulding@usc.edu</p>	<p>Cheng, C.-F. <i>et al. J. Clin. Invest.</i>; published online Oct. 24, 2011; doi:10.1172/JCI46475 Contact: Wei Li, Keck School of Medicine of the University of Southern California, Los Angeles, Calif. e-mail: wli@usc.edu</p>